Nova Patents
LU90710I2

Galanthamine or analogues thereof for treating alzheimer's disease

Abstract

Alzheimer's disease may be treated with galanthamine.

Term

Term ended

Projected expiry passed 3 January 2021, 5.7 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

46 members in 15 offices

This recordMember, by publication datePriority claim5 more offices are in the list below

Priority claims3

Priority claims
DocumentOfficeKindDate
81914186United States of AmericaA
81914186United States of AmericaA
US19860819141–––

Members46

Family members, oldest first
DocumentOfficeKind
US4663318AUnited States of AmericaA
AU6760987AAustraliaA
EP0236684A2European Patent Office (EPO)A2
JPS62215527AJapanA
ES2000428A4SpainA4
DE236684T1GermanyT1
GR880300077T1GreeceT1
WO8808708A1World Intellectual Property Organization (WIPO)A1
AU1808488AAustraliaA
EP0236684A3European Patent Office (EPO)A3
DK549189D0DenmarkD0
KR890701107ARepublic of KoreaA
DK549189ADenmarkA
AU593051B2AustraliaB2
EP0363415A1European Patent Office (EPO)A1
JPH02503794AJapanA
EP0236684B1European Patent Office (EPO)B1
AT76294TAustriaT
ATE76294T1AustriaT1
DE3779149D1GermanyD1
AU632458B2AustraliaB2
EP0363415A4European Patent Office (EPO)A4
GR3005447T3GreeceT3
ES2000428T3SpainT3
JPH08778B2JapanB2
CA1338326CCanadaC
JP2755403B2JapanB2
FI102756BFinlandB
FI102756B1FinlandB1
KR100195399B1Republic of KoreaB1
US6150354AUnited States of AmericaA
LU90710I2This recordLuxembourgI2
DE10199020I1GermanyI1
US6268358B1United States of AmericaB1
US6319919B1United States of AmericaB1
US6569848B1United States of AmericaB1
NL300140I1Netherlands (Kingdom of the)I1
US2004023984A1United States of AmericaA1
NL300140I2Netherlands (Kingdom of the)I2
DE10199020I2GermanyI2
DK175839B1DenmarkB1
AT411026TAustriaT
ATE411026T1AustriaT1
EP0363415B1European Patent Office (EPO)B1
DE3856594D1GermanyD1
ES2000428T9SpainT9